- Home
- PHAT
as 11-15-2024 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 1.2B | IPO Year: | 2019 |
| Target Price: | $22.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.07 - $19.71 | Next Earning Date: | 11-07-2024 |
| Revenue: | $26,270,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6714.96% | Revenue Growth (next year): | 293.69% |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
GuruFocus.com
9 days ago
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
MT Newswires
9 days ago
Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens
Zacks
10 days ago
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
10 days ago
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
GuruFocus.com
11 days ago
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For
GlobeNewswire
13 days ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Simply Wall St.
16 days ago
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%
GlobeNewswire
20 days ago
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.